In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
REGULATORY
Japan OKs Honebuto Paper with Softened Phrasing on CEA, Sign of Change to Social Security Budgeting
Japan’s Cabinet approved the 2025 Basic Policy on Economic and Fiscal Management and Reform (honebuto) on June 13. The final paper kept the previous draft’s toned-down language on reforming the cost-effectiveness assessment (CEA) scheme, as well as a budget policy…
To read the full story
Related Article
- JPMA Ready to Engage with Government on CEA Debates: Statement
June 16, 2025
- Latest Honebuto Draft Erases “Expansion” of CEA after LDP Pushback
June 12, 2025
- Ruling Bloc, Ishin Agree to Discuss Coverage of OTC-Like Drugs
June 12, 2025
- LDP Lawmakers Push Back on Honebuto Draft over CEA, Social Security Budgeting
June 10, 2025
- Honebuto Draft Urges Promotion of Drug Innovation, but Spells Out CEA Expansion Too
June 9, 2025
- Early Honebuto Draft Contains CEA Expansion, Ramp-Up of FIH Trial Sites
June 4, 2025
- Honebuto Outline Includes “Raise in Official Prices,” but Details Yet Unknown
May 27, 2025
REGULATORY
- MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
November 6, 2025
- Japan Launches Growth Strategy Council, Sets Drug Discovery as Priority Field
November 5, 2025
- MHLW Clarifies When Generic Drug Mergers Must Be Reviewed by Antitrust Regulator
November 5, 2025
- LDP Project Team Urges Economic Measures Reflecting Price Pressures
November 4, 2025
- Former Flagship Brands among 506 Drugs Set for Delisting
November 4, 2025
Japan’s Ministry of Health, Labor and Welfare (MHLW) proposed a full review of the so-called “G1/G2” rule — a framework…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
Japan’s Central Social Insurance Medical Council (Chuikyo) on October 15 approved the reimbursement listing of five new medicines, with the…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…